It was late 2020 when David decided to talk to his GP about getting a prescription for medicinal cannabis.
He’d been diagnosed with fibromyalgia — a condition characterised by widespread pain and tenderness in the body — and had been mostly self-medicating with cannabis he’d bought illegally.
“Fibromyalgia is quite debilitating,” he said.
“It causes random pain spots in the body … my shins will be numb and then just feel like they’re on fire at the same time.”
The condition, which can be difficult to diagnose, is often accompanied by fatigue and altered sleep, memory and mood.
David — not his real name — says he was feeling constantly fatigued, struggling to manage his illness alongside work and taking care of his disabled partner.
“By about two o’clock in the afternoon, I just wanted to fall asleep,” he said.
After getting the green light from his GP, David began using cannabis oils and herbal products.
He found they helped to “mask the symptoms” of fibromyalgia and improve his sleep.
“Eventually my body adjusted and I was able to just have very small amounts [of cannabis],” he said.
Prescriptions grow as access eases
David is one of tens of thousands of Australians who access cannabis legally.
Data from the Therapeutic Goods Administration (TGA) shows prescriptions for medicinal cannabis doubled from 2020 to 2021, with more than 122,000 prescriptions written last year alone.
It’s a significant jump from just a few years ago. In 2018, roughly 2,500 prescriptions were written for the entire year.
Melbourne GP Vicki Kotsirilos — the first authorised GP prescriber of medicinal cannabis in Australia — said prescriptions had likely increased because the TGA application process had been “streamlined” and patient demand had grown.
“It was exceptionally hard in the beginning. I was not able to get very many permits,” said Dr Kotsirilos, an associate professor at Western Sydney University.
“Since the end of 2018, the TGA introduced an online permit system, and extended the duration [of permits] from three to six months to one year, and now even up to two years.
“In the past, we also had to get a permit for every single product … now, it’s generically prescribed.”
In other words, a GP can prescribe a product if it’s based on an approved category of cannabinoid content (eg. CBD-only treatment) for that patient, rather than having to get approval for each new product.
In Australia, there are only two cannabis-based prescription medicines on the Australian Register of Therapeutic Goods.
One is prescribed to treat rare, drug-resistant forms of epilepsy that begin in childhood, the other as a muscle relaxant for people with multiple sclerosis.
The vast majority of cannabis products are unregistered drugs, which require approval under the TGA’s Special Access Scheme (or via its Authorised Prescriber Scheme).
These products, of which there are more than 250, contain CBD or THC (or both), and come in the form of oils, capsules or dried flowers to be vaporised.
Data shows most prescriptions are for chronic pain, anxiety, cancer-related symptoms, and insomnia.
Growth in prescription reflects ‘unmet health needs’
Jennifer Martin, physician and director of the Australian Centre for Cannabinoid Clinical and Research Excellence, said she wasn’t surprised that medicinal cannabis prescriptions had increased substantially.
“The numbers have gone up exponentially, and looking at other countries, it was expected that would happen here too.”
Professor Martin said the fact most prescriptions were being written for chronic pain and anxiety reflected large “unmet health needs” in the community.
“When we see people like this in our clinical practice, they’re sometimes on seven to 10 medications and their symptoms don’t go away,” she said.
“They’re sometimes just waiting for the next new chemical to arrive.”
The problem, she said, was that in many cases, chronic pain and anxiety-related conditions were not “satiated by biochemicals” alone, and usually required psychological therapy and environmental changes to help address “underlying issues”.
“It may just be that [medicinal cannabis] is getting them through their current situation,” she said.
“It’s not a problem in the sense that people often use chemicals in the short term to cope with things.
Professor Martin said many people faced limited access to mental health services and pain management support.
“The reality is, it costs a lot of money, and they have to wait six months for a [psychology] appointment. It’s the same with pain clinics.”
